1. Home
  2. CLB vs CADL Comparison

CLB vs CADL Comparison

Compare CLB & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

HOLD

Current Price

$10.84

Market Cap

864.2M

Sector

N/A

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$9.75

Market Cap

754.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLB
CADL
Founded
1936
1999
Country
United States
United States
Employees
3300
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
864.2M
754.7M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
CLB
CADL
Price
$10.84
$9.75
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$12.50
$19.00
AVG Volume (30 Days)
911.1K
2.0M
Earning Date
04-29-2026
05-14-2026
Dividend Yield
0.23%
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
$526,520,000.00
$125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.51
N/A
52 Week Low
$9.72
$4.35
52 Week High
$20.36
$11.36

Technical Indicators

Market Signals
Indicator
CLB
CADL
Relative Strength Index (RSI) 34.29 60.25
Support Level $10.40 $4.89
Resistance Level $17.05 N/A
Average True Range (ATR) 0.59 0.64
MACD 0.03 0.05
Stochastic Oscillator 18.88 54.81

Price Performance

Historical Comparison
CLB
CADL

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: